NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

about

Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.Polypeptoids: A perfect match for molecular definition and macromolecular engineering?

P2860

Q35532355-BE6BC4AD-CBF0-4BA3-808B-23C81E1735FC Q57352822-796CB19C-E731-449B-932A-CFECD681E0D3

P2860

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

Item

http://www.wikidata.org/entity/Q35627471

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@ast

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@en

type

Item

label

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@ast

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@en

prefLabel

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@ast

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@en

P1476

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

@en

P2093

Annelise E Barron

http://www.w3.org/2001/XMLSchema#string

Minyoung Park

http://www.w3.org/2001/XMLSchema#string

Theodore S Jardetzky

http://www.w3.org/2001/XMLSchema#string

P2860

Structural characterization of the human respiratory syncytial virus fusion protein core

Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors

Improving SH3 domain ligand selectivity using a non-natural scaffold.

New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites.

A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery.

Screening for peptide drugs from the natural repertoire of biodiverse protein folds.

Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association.

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

Pegylation: a novel process for modifying pharmacokinetics.

New peptidomimetic polymers for antifouling surfaces.

P304

688-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BIP.21607

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51899435

http://www.w3.org/2001/XMLSchema#string

P698

22180913

http://www.w3.org/2001/XMLSchema#string

P932

3243944

http://www.w3.org/2001/XMLSchema#string

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

about

P2860

P2860

NMEGylation: a novel modification to enhance the bioavailability of therapeutic peptides.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932